Jeffrey D Osborne Net Worth

The estimated Net Worth of Jeffrey D Osborne is at least $10.4 Million dollars as of 18 January 2012. Jeffrey Osborne owns over 20,064 units of Accenture plc stock worth over $9,285,317 and over the last 14 years Jeffrey sold ACN stock worth over $1,098,705.

Jeffrey Osborne ACN stock SEC Form 4 insiders trading

Jeffrey has made over 1 trades of the Accenture plc stock since 2012, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 20,064 units of ACN stock worth $1,098,705 on 18 January 2012.

The largest trade Jeffrey's ever made was selling 20,064 units of Accenture plc stock on 18 January 2012 worth over $1,098,705. On average, Jeffrey trades about 1,433 units every 0 days since 2011. As of 18 January 2012 Jeffrey still owns at least 26,506 units of Accenture plc stock.

You can see the complete history of Jeffrey Osborne stock trades at the bottom of the page.

What's Jeffrey Osborne's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ACCENTURE, 161 N. CLARK STREET, CHICAGO, IL, 60601.

Insiders trading at Accenture plc

Over the last 13 years, insiders at Accenture plc have traded over $571,571,901 worth of Accenture plc stock and bought 20,000 units worth $1,439,800 . The most active insiders traders include Beth E Mooney, Venkata S M Renduchintala, and Pierre Nanterme. On average, Accenture plc executives and independent directors trade stock every 8 days with the average trade being worth of $2,487,902. The most recent stock trade was executed by Ellyn Shook on 23 July 2024, trading 5,000 units of ACN stock currently worth $1,649,100.

What does Accenture plc do?

Accenture plc is an Irish-American professional services company based in Dublin, specializing in information technology services and consulting. A Fortune Global 500 company, it reported revenues of $61.6 billion in 2022.

Complete history of Jeffrey Osborne stock trades at Accenture plc

Accenture plc executives and stock owners

Accenture plc executives and other stock owners filed with the SEC include:

• David Rowland,
  Executive Chairman of the Board
• Julie T. Spellman Sweet,
  CEO & Chairman
• Julie Sweet,
  Chief Executive Officer, Director
• Gianfranco Casati,
  Group Chief Executive - Growth Markets
• Gianfranco Casati,
  Chief Exec. Officer of Growth Markets
• KC McClure,
  Chief Financial Officer
• Jean-Marc Ollagnier,
  Chief Exec. Officer of Europe
• Kathleen R. McClure,
  Chief Financial Officer
• David P. Rowland,
  Exec. Chairman & Advisor to CEO
• Paula Price,
  Independent Director
• Jaime Ardila,
  Independent Director
• Nancy McKinstry,
  Independent Director
• Tracey Travis,
  Independent Director
• Gilles Christian Pelisson,
  Lead Independent Director
• Arun Sarin,
  Independent Director
• Herbert Hainer,
  Independent Director
• Venkata Renduchintala,
  Independent Director
• Frank Tang,
  Independent Director
• Joel Unruch,
  Chief Compliance Officer, General Counsel, Secretary
• James Etheredge,
  Chief Executive, North America
• Domingo Miron,
  Group Chief Executive - Financial Services
• Simon Eaves,
  Group Chief Executive - Products Operating Group
• John Walsh,
  Group Chief Executive Officer - Communications, Media and Technology
• Richard Clark,
  Chief Accounting Officer, Corporate Controller
• Ellyn Shook,
  Chief Human Resource Officer, Chief Leadership Officer
• Johan Deblaere,
  Chief Operating Officer, Chief Executive - Europe
• Jean-Marc Ollagnier,
  Group Chief Executive - Resources Operating Group
• Daniel London,
  Group Chief Executive - Health & Public Service Operating Group
• Jill Kramer,
  Chief Marketing & Communications Officer
• Joel Unruch,
  Gen. Counsel & Corp. Sec.
• Joel F. Unruch,
  Gen. Counsel & Corp. Sec.
• Angie Park,
  Managing Director & Head of Investor Relations
• Paul R. Daugherty,
  Group Chief Exec. of Technology & CTO
• Richard P. Clark,
  Chief Accounting Officer & Chief Transformation Officer – Bus. Enablement
• Johan G. Deblaere,
  Chief Operating Officer
• Omar Abbosh,
  Grp Chief Exec-Com, Med & Tech
• Charles H Giancarlo,
  Director
• Dina Dublon,
  Director
• William L Kimsey,
  Director
• Robert E Sell,
  Grp Chief Exec-Com, Med & Tech
• Marjorie Magner,
  Director
• Chad T Jerdee,
  General Counsel and CCO
• Wulf Von Schimmelmann,
  Director
• Blythe J Mcgarvie,
  Director
• Beth E Mooney,
  Director
• Leonardo Framil,
  CEO-Growth Markets
• Melissa A Burgum,
  Chief Accounting Officer
• Kathleen R Mc Clure,
  Chief Financial Officer
• Stephen J Rohleder,
  Group Chief Exec-Health & PS
• Mark Moodystuart,
  Director
• Nobuyuki Idei,
  Director
• Michael J Salvino,
  Group Chief Exec-Bus Proc Out
• Shawn Collinson,
  Sr Managing Dir-Growth & Strat
• Martin I Cole,
  Grp Chief Exec-Comm & HighTech
• 'T Noordende Alexander M Van,
  Group Chief Exec-Products
• Pierre Nanterme,
  Chief Executive Officer
• Jill Smart,
  Chief Human Resources Officer
• Richard Lumb,
  Group Chief Executive-Fin Serv
• Robert I Lipp,
  Director
• William D Green,
  Chairman
• Anthony G Coughlan,
  Principal Accounting Officer
• Pamela J. Craig,
  Chief Financial Officer
• Dennis F Hightower,
  Director
• Jeffrey D Osborne,
  Chief Performance Officer
• Kevin M Campbell,
  Group Chief Exec-Technology
• Robert N Frerichs,
  Group Chief Exec-North America
• Martin Brudermueller,
  Director
• Alan C. Jope,
  Director
• Angela Beatty,
  Chief Leadership & HR Officer
• Manish Sharma,
  CEO-Americas